Drug Trial Radar · NCT01585298
STudy to vAlidate telemetRic ECG Systems for firsT Dose Administration of Fingolimod (START)
Last checked: Nov 20, 2026Latest source record: Sep 23, 2019 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
6,998
Actual
Start
Apr 29, 2012
Primary completion
Dec 12, 2016
Study completion Dec 12, 2016
Sponsor
- Lead sponsor
- Novartis PharmaceuticalsNovartis (NVS)
- Sponsor type
- Industry
- First posted
- Apr 25, 2012
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study evaluated bradycardiac events during first dose observation of fingolimod in MS patients.
Conditions
- Multiple Sclerosis
Interventions
FTY720Drug
Primary outcomes
What the sponsor says the trial is designed to measure.
- Participants With 2nd or 3rd Degree Atrioventricular (AV) BlockTime frame: baseline, during 6 hour monitoring post first dose observation
- Number of Patients With Heart Rate Below 45 Beats Per Minute (BPM)Time frame: baseline during 6 hour monitoring post dose
Locations
258 sites in 1 country. Site status is shown where the registry gives one.
Novartis Investigative Site
Aachen, Germany
Novartis Investigative Site
Aachen, Germany
Novartis Investigative Site
Aalen, Germany
Novartis Investigative Site
Aalen-Wasseralfingen, Germany
Novartis Investigative Site
Abensberg, Germany
Novartis Investigative Site
Achim, Germany
Novartis Investigative Site
Aichach, Germany
Novartis Investigative Site
Altenburg, Germany
Novartis Investigative Site
Alzenau in Unterfranken, Germany
Novartis Investigative Site
Andernach, Germany
Novartis Investigative Site
Asbach, Germany
Novartis Investigative Site
Aschaffenburg, Germany
Novartis Investigative Site
Augsburg, Germany
Novartis Investigative Site
Bad Berka, Germany
Novartis Investigative Site
Bad Hersfeld, Germany
Novartis Investigative Site
Bad Homburg, Germany
Novartis Investigative Site
Bad Honnef, Germany
Novartis Investigative Site
Bad Krozingen, Germany
Novartis Investigative Site
Bad Mergentheim, Germany
Novartis Investigative Site
Bad Saarow, Germany
Novartis Investigative Site
Bad Wildbad, Germany
Novartis Investigative Site
Bamberg, Germany
Novartis Investigative Site
Bayreuth, Germany
Novartis Investigative Site
Berg, Germany
Novartis Investigative Site
Bergisch Gladbach, Germany
Novartis Investigative Site
Berlin, Germany
Novartis Investigative Site
Berlin, Germany
Novartis Investigative Site
Berlin, Germany
Novartis Investigative Site
Berlin, Germany
Novartis Investigative Site
Berlin, Germany
Novartis Investigative Site
Berlin, Germany
Novartis Investigative Site
Berlin, Germany
Novartis Investigative Site
Berlin, Germany
Novartis Investigative Site
Berlin, Germany
Novartis Investigative Site
Berlin, Germany
Novartis Investigative Site
Berlin, Germany
Novartis Investigative Site
Berlin, Germany
Novartis Investigative Site
Berlin, Germany
Novartis Investigative Site
Berlin, Germany
Novartis Investigative Site
Berlin, Germany
Showing 40 of 258 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.